Investor Relations

Breakthrough Oxygenation

Investment Highlights

Innovative and cost-effective
technology for respiratory support
Early elevation of oxygen saturation
levels to minimize the need for
mechanical ventilation
Designed to be administered while
patients are awake and
breathing spontaneously
Aims to reduce
length of hospital stays
and costs
Total addressable market
of $20 billion
Experienced and committed
management team

Latest news and press releases

September 30, 2021

Inspira Technologies to Host COVID-19 Virtual Conference on October 6

September 22, 2021

Inspira Technologies’ “Artificial Lung” To Acquire A Digital Edge: The Company Contracted GlobalLogic, A Hitachi Group Company, For Advanced Digital Product Engineering Services

SEC Filings

Research Coverage

Bank
Analyst
Phone
E-mail
Aegis Capital
Nathan Weinstein, CFA
646-502-2522
nweinstein@aegiscap.com

These reports are prepared by independent analysts. Inspira does not endorse or distribute such reports and takes no responsibility for the accuracy or completeness of the material contained in the reports. Please note that any opinions, estimates or forecasts regarding the company’s performance made by these analysts are theirs alone and do not represent opinions, forecasts, or predictions of Inspira Technologies.

Get in Touch!

    Ha-Tidhar St 2, Ra'anana, Israel

    I consent to receive emails from Inspira Technologies Oxy B.H.N LTD. To request removal from the mailing list at any time, please send an email to info@inspirao2.com. You can find out about your rights and privacy choices, and how we use your information in our Privacy Policy.